This week, a proposal from the Centers for Medicare & Medicaid Services (CMS) to maintain flat reimbursement rates for Medicare Advantage health plans in 2027 has sparked backlash from the health insurance industry. Many stakeholders are expressing concern that these changes could lead to service reductions for seniors, while health policy experts assert that the plan might effectively curb long-standing overcharging practices within the program.
On January 26, CMS officials revealed plans to alter payment rates, suggesting a mere 0.1 percent increase, falling significantly short of industry expectations. The announcement sent stock prices tumbling for major insurers, such as UnitedHealth Group and Humana. Industry representatives quickly highlighted potential consequences for recipients aged 65 and older, warning that the absence of additional government funding could lead to diminished services.
Medicare Advantage functions by allowing the federal government to pay private insurers to oversee healthcare for seniors and disabled individuals. A notable aspect of the proposal involves proposed restrictions on “chart reviews”—a practice through which insurance plans adjust patient diagnoses, sometimes leading to inflated payments. Critics have denounced these practices for inciting billions in overpayments, as highlighted by a recent settlement involving Kaiser Permanente. The nonprofit health system agreed to pay $556 million due to allegations of inaccurately adding diagnoses for about half a million patients, a maneuver that purportedly generated approximately $1 billion in unjust payments, although Kaiser did not concede to any wrongdoing.
Healthcare policy analyst Spencer Perlman remarked on the administration’s commitment to addressing overpayments, suggesting that the proposal represents a serious attempt to address inefficiencies within the Medicare Advantage framework. CMS Administrator Mehmet Oz emphasized that these proposed changes are intended to ensure accuracy in payments and protect taxpayer dollars, with a focus on genuinely addressing health needs.
The pushback from the insurance industry was immediate and fierce, particularly against the decision to freeze payment rates. Chris Bond, a spokesperson for AHIP (formerly America’s Health Insurance Plans), cautioned that finalizing such a proposal could lead to higher costs and diminished benefits for up to 35 million seniors and disabled individuals when they renew their plans in late 2026.
Despite industry claims that payment adjustments typically force plans to reduce benefits, analysts like David Meyers argue that this narrative often does not reflect reality, noting that many plans remain profitable, albeit at lower margins than anticipated. Over the last decade, investigative reports and whistleblower complaints have unveiled a pattern of “upcoding” wherein plans inflate the severity of their members’ health status to obtain higher payments, a practice that has raised scrutiny from auditors and regulators.
Federal audits have consistently shown that many insurance plans utilize chart reviews to increase—rather than decrease—diagnoses. A 2019 inspector general report found that over 99 percent of such reviews resulted in added diagnoses, which accounted for an estimated $6.7 billion in payments that year alone.
This isn’t the first time CMS has sought to limit chart reviews. Previous attempts have faced significant resistance from the insurance industry, illustrating a longstanding struggle between regulatory intentions and industry lobbying efforts. Observers are cautiously optimistic about the current proposal’s potential impact, while also recognizing the industry’s historical ability to mitigate regulatory changes through lobbying and public relations campaigns.
As CMS begins to accept public comments on the proposed adjustments, the final decision is expected by early April. Health advocacy groups are hopeful that any finalized restrictions could represent a pivotal shift in curtailing overpayments to Medicare Advantage plans, a change many see as long overdue. The upcoming months will reveal how seriously the current administration is willing to pursue reforms within an industry notorious for its pushback against tighter regulations.
